Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE)

Fig. 3

PD-1 is not detectable on peripheral blood T cells or tumor-infiltrating T cells after six and nine weeks of pembrolizumab, respectively. (a) Representative PD-1 staining of CD4 and CD8 T cells from peripheral blood at baseline and the first six weeks of pembrolizumab. (b) Representative FACS from patients with PD-1 blocked by week six and week nine of treatment. Gated on total CD3+ lymphocytes in tumor biopsies. Clone of anti-PD-1 used for flow cytometry was EH12.2H7

Back to article page